Hadrien works closely with many different types of clients in Belgium's thriving pharma and biotech landscape. From start-ups to multinationals, his advice helps client identify how to success and grow as a business.
An experienced corporate lawyer who specialises in mergers and acquisitions (M&A), venture capital, public offerings, corporate reorganisations, corporate and security law, and corporate finance, Hadrien is a Partner in Osborne Clarke’s Brussels corporate team. In this role, he advises on public and private M&As, and acts for clients on a wide variety of transactional matters and restructurings, including setting-up, financing, reorganising, acquiring, or liquidating business ventures, also providing litigation services in these areas.
Hadrien is constantly close to the cutting-edge of biotechnology medical diagnostics and medtech. For example, he has been advising OncoDNA, a cancer theranostic company and winner of the Biotech Award of Deloitte’s 2020 Technology Fast50 competition, for several years as they expand their business to support oncologists in treatment decisions for patients. Other clients active in biotech, medtech and medical diagnostics include Bone Therapeutics, Biosourcing, ImmunXperts, Auxin Surgery, Kitozyme and BepharBel Manufacturing.
Along with his colleagues in the Osborne Clarke life sciences team, he is an active member of the Biowin consortium and a presenter at Essenica/Agoria on digital transformation in the life sciences industry.
While an unquestioned specialist in the field of life sciences, Hadrien has significant expertise in other areas, including technology, media and communications, and transportation and automotive, again regularly advising on M&A transactions, joint ventures and investment schemes. His experience in these sectors was gained on the international stage, having worked as an Associate in Hong Kong in 2015, and carrying out a secondment at a leading provider of specialised transportation and logistics in 2014.
European Healthcare Investor
Representing a European Healthcare investor, and the lead investor in this matter, in the EUR 18 million series B financing of a pioneering medical device company
Medical Diagnostics Company
Assisting a medical diagnostics company with its acquisition of a Spanish entity as well as with its fundraising through repayable advances
Belgian Immunology Company
Representing a Belgian Immunology company on its latest capital round
Advised a Belgian pharmaceutical company on a new partnership with two private investors
Advised Visiomed, company listed on NYSE Alternext Paris, on the Belgian law aspects of their acquisition of business units from Omega Pharma
Advised a technology company on its acquisition of an independent cybersecurity company
Assisting Accountable on corporate and tax shelter issues in the framework of a seed financing and on the drafting of a Subscription and Shareholders Agreement with a view to its Series B financing
A staffing company
Advising a staffing company on its investment in a developer of online tools to manage flexible staff
Global media group
Advising a global media group on its acquisition of a Belgian life stream company
Belgian insurance company
Advising a Belgian insurance company on its acquisition of an insureTech company
Advising the shareholders of a communication company on its aborted sale to a Belgian media group
Global aircraft company
Assisting a global aircraft company with various corporate advice
Manufacturer of electric vehicles
Assisting a manufacturer of electric vehicles in setting-up a joint venture in Belgium
Assisting various public entities with the launch of Social Impact Bonds
Political agreement reached on the EU's Markets in Crypto Assets Regulation
Compassionate Use in Europe
New legal obligations imposed for virtual asset service providers in Belgium
Future screening of foreign direct investments takes shape in Belgium
A federal proposal for FDI screening in Belgium will supplement an existing Flemish scheme
The Shareholders Rights Directive (SRD II): what you should know and what you can do
On 28 April 2020, the Belgian Parliament proclaimed an act transposing Directive (EU) 2017/828 - also known as the second...
The SRD II and Remuneration Policy
The new remuneration policy requirements: what you should know and what you can do Updated May 2021
The SRD II and Remuneration Report
The new remuneration report requirements: what you should know and what you can do
Update on UBO register requirements in Belgium: new Royal Decree fine-tunes obligations
In Belgium, all Belgian companies, (I)NPOs, foundations, trusts and similar legal entities are under an obligation to register their ultimate...
Considerations and best practices for Belgian listed biotech companies when assessing and disclosing inside information (Part 4)
Good practices recommended by the Belgian Financial Services and Markets Authority (FSMA)
Considerations and best practices for Belgian listed biotech companies when assessing and disclosing inside information
What are the best practices for biotech companies in relation to inside information and the Belgian Financial Services and Markets...
Considerations and best practices for Belgian listed biotech companies when assessing and disclosing inside information (Part 2)
How does the Belgian Financial Services and Markets Authority (FSMA) determine what qualifies as inside information for biotech companies?
Remote participation at shareholders' meetings is facilitated under new Belgian company rules
The Law of 20 December 2020 amends the Belgian Code on Companies and Associations (BCCA) in order to facilitate remote...